FOXO3 and lung carcinoma: This complexity of competing protein expression emphasizes the prospect of FOXO3a signaling pathway point for lung cancer cell growth inhibition, presenting β-Elemene as a potential therapeutic due to its mechanism of action (Sun et al., 2020[5]).